Drug Type Small molecule drug |
Synonyms selective rapidly accelerated fibrosarcoma (RAF) murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor, FORE-8394, FORE8394 + [4] |
Target |
Mechanism BRAF inhibitors(Serine/threonine-protein kinase B-raf inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationFast Track (US), Orphan Drug (US) |
Molecular FormulaC25H21F3N6O3S |
InChIKeyYYACLQUDUDXAPA-MRXNPFEDSA-N |
CAS Registry1393466-87-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
BRAF mutation Solid Tumors | Phase 2 | US | 21 Feb 2023 | |
BRAF mutation Solid Tumors | Phase 2 | CA | 21 Feb 2023 | |
BRAF mutation Solid Tumors | Phase 2 | FR | 21 Feb 2023 | |
BRAF mutation Solid Tumors | Phase 2 | DE | 21 Feb 2023 | |
BRAF mutation Solid Tumors | Phase 2 | IT | 21 Feb 2023 | |
BRAF mutation Solid Tumors | Phase 2 | KR | 21 Feb 2023 | |
BRAF mutation Solid Tumors | Phase 2 | ES | 21 Feb 2023 | |
BRAF mutation Solid Tumors | Phase 2 | SE | 21 Feb 2023 | |
BRAF mutation Solid Tumors | Phase 2 | GB | 21 Feb 2023 | |
Glioma | Phase 2 | US | 01 Apr 2015 |